首页> 美国卫生研究院文献>PharmacoEconomics Open >Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

【2h】

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

机译：加拿大Nivolumab联合Ipilimumab联合作为一线治疗晚期黑素瘤患者的经济评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveOur objective was to evaluate the cost effectiveness of the combination of nivolumab and ipilimumab, referred to as “Regimen”, as a first-line treatment for patients with advanced melanoma from the perspective of Canada’s public healthcare system.

机译：目的我们的目标是从加拿大的公共医疗体系的角度评估尼古鲁单抗和依匹莫单抗（称为“ Regimen”）作为晚期黑色素瘤患者的一线治疗的成本效益。

著录项

期刊名称 PharmacoEconomics Open
作者
Peter L. Quon; Ying Xiao; Sonja Sorensen; Amir Abbas Tahami Monfared;
展开▼
作者单位

展开▼
年(卷),期 2019(3),3
年度 2019
页码 321–331
总页数 11
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN [J] . Baker T. M., Paly V. F., Thybo S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：诺和单抗联合依比单抗在瑞典先发性黑素瘤一线治疗中的成本效益
2. Milestones in the Treatment of malignant Melanoma Nivolumab in the Adjuvant and as a Combination Therapy with Ipilimumab in Patients with advanced Melanoma [J] . Sankawa Yuri Oncology research and treatment. . 2019,第7a8期

机译：治疗佐剂中恶性黑素瘤Nivolumab的里程碑，作为高素序瘤患者的IPILIMIMAB的联合治疗
3. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma [J] . Hannah L. Buckley, Fiona J. Collinson, Gemma Ainsworth, BMC Cancer . 2019,第1期

机译：棱镜方案：Nivolumab的随机期II试验与替代调度的IPILIMIMAB在先进或转移性肾细胞癌患者的一线治疗中
4. Long-term effects of laser-imiquimod combination in the treatment of late-stage melanoma patients [C] . Mark F. Naylor, Wei R. Chen Biophotonics and immune responses VII. . 2012

机译：咪喹莫特激光联合治疗晚期黑色素瘤患者的远期疗效
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma [O] . F Stephen Hodi, Jason Chesney, Anna C Pavlick, -1

机译：一项评估尼古鲁单抗和伊匹单抗联合单用伊匹单抗治疗晚期黑色素瘤患者的随机2期试验的两年总生存率
7. Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada [O] . Peter L. Quon, Ying Xiao, Sonja Sorensen, 2019

机译：Nivolumab Plus Ipilemimab组合作为加拿大晚期黑素瘤患者的一线治疗的经济评价

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

摘要

著录项

相似文献

相关主题

期刊订阅